File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Scopus: eid_2-s2.0-0023867190
- PMID: 3342467
- WOS: WOS:A1988M058100015
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Chemotherapy for relapsed and resistant acute nonlymphoblastic leukemia. Effect of ATA, an amsacrine-containing regime
Title | Chemotherapy for relapsed and resistant acute nonlymphoblastic leukemia. Effect of ATA, an amsacrine-containing regime |
---|---|
Authors | |
Issue Date | 1988 |
Publisher | Springer. The Journal's web site is located at http://www.springer.com/medicine/oncology/journal/280 |
Citation | Cancer Chemotherapy And Pharmacology, 1988, v. 21 n. 1, p. 68-70 How to Cite? |
Abstract | Twenty-nine evaluable patients with acute nonlymphoblastic leukemia (ANLL), either in relapse or resistant to initial induction therapy (ara C, daunorubicin + etoposide), received the ATA regime consisting of 100 mg/m2 per day Ara C by i.v. infusion for 4-5 days, 100 mg/m2 per day thioguanine orally for 4-5 days, and 100 mg/m2 per day amsacrine i.v. for 2-5 days. Each patient received 1-6 courses (median, 2) of the regime. There were 7 (24%) complete responders, and their duration of responses were 2, 2, 2, 5, 9+, 19, and 24+ months. The complete remission (CR) rate of patients who had a previous CR beyond 6 months (6/13, 46%) was significantly better (X2 = 4.25, p < 0.05) than that of those who had previously relapsed within 6 months or were refractory to primary induction chemotherapy (1/16, 6%). The two groups of patients had similar patterns of treatment failure. Myelosuppression was the major toxic side effect, and nonhematological toxicities were mild and acceptable. |
Persistent Identifier | http://hdl.handle.net/10722/161760 |
ISSN | 2023 Impact Factor: 2.7 2023 SCImago Journal Rankings: 0.869 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Liang, R | en_US |
dc.contributor.author | Chan, TK | en_US |
dc.contributor.author | Todd, D | en_US |
dc.date.accessioned | 2012-09-05T05:14:43Z | - |
dc.date.available | 2012-09-05T05:14:43Z | - |
dc.date.issued | 1988 | en_US |
dc.identifier.citation | Cancer Chemotherapy And Pharmacology, 1988, v. 21 n. 1, p. 68-70 | en_US |
dc.identifier.issn | 0344-5704 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/161760 | - |
dc.description.abstract | Twenty-nine evaluable patients with acute nonlymphoblastic leukemia (ANLL), either in relapse or resistant to initial induction therapy (ara C, daunorubicin + etoposide), received the ATA regime consisting of 100 mg/m2 per day Ara C by i.v. infusion for 4-5 days, 100 mg/m2 per day thioguanine orally for 4-5 days, and 100 mg/m2 per day amsacrine i.v. for 2-5 days. Each patient received 1-6 courses (median, 2) of the regime. There were 7 (24%) complete responders, and their duration of responses were 2, 2, 2, 5, 9+, 19, and 24+ months. The complete remission (CR) rate of patients who had a previous CR beyond 6 months (6/13, 46%) was significantly better (X2 = 4.25, p < 0.05) than that of those who had previously relapsed within 6 months or were refractory to primary induction chemotherapy (1/16, 6%). The two groups of patients had similar patterns of treatment failure. Myelosuppression was the major toxic side effect, and nonhematological toxicities were mild and acceptable. | en_US |
dc.language | eng | en_US |
dc.publisher | Springer. The Journal's web site is located at http://www.springer.com/medicine/oncology/journal/280 | en_US |
dc.relation.ispartof | Cancer Chemotherapy and Pharmacology | en_US |
dc.subject.mesh | Acute Disease | en_US |
dc.subject.mesh | Adolescent | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Amsacrine - Administration & Dosage - Adverse Effects - Therapeutic Use | en_US |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols - Adverse Effects - Therapeutic Use | en_US |
dc.subject.mesh | Cytarabine - Administration & Dosage - Adverse Effects - Therapeutic Use | en_US |
dc.subject.mesh | Drug Resistance | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Leukemia - Drug Therapy | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle Aged | en_US |
dc.subject.mesh | Recurrence | en_US |
dc.subject.mesh | Thioguanine - Administration & Dosage - Adverse Effects - Therapeutic Use | en_US |
dc.title | Chemotherapy for relapsed and resistant acute nonlymphoblastic leukemia. Effect of ATA, an amsacrine-containing regime | en_US |
dc.type | Article | en_US |
dc.identifier.email | Liang, R:rliang@hku.hk | en_US |
dc.identifier.authority | Liang, R=rp00345 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.pmid | 3342467 | - |
dc.identifier.scopus | eid_2-s2.0-0023867190 | en_US |
dc.identifier.volume | 21 | en_US |
dc.identifier.issue | 1 | en_US |
dc.identifier.spage | 68 | en_US |
dc.identifier.epage | 70 | en_US |
dc.identifier.isi | WOS:A1988M058100015 | - |
dc.publisher.place | Germany | en_US |
dc.identifier.scopusauthorid | Liang, R=26643224900 | en_US |
dc.identifier.scopusauthorid | Chan, TK=7402687762 | en_US |
dc.identifier.scopusauthorid | Todd, D=7201388182 | en_US |
dc.identifier.issnl | 0344-5704 | - |